| Date | Title | Description |
| 16.05.2024 | Peptomyc has been granted 40.000 € within the ACTIVA startups | Read the full press release here:
|
| 16.05.2024 | Hospital Clínic Barcelona Collaborates with Mediktor for Improved Patient Assistance in Tropical Diseases | Read the full press release here:
https://www.mediktor.com/es/news/news/hospital-clinic-barcelona-collaborates-with-mediktor-for-improved-patient-assistance-in-tropical-diseases |
| 16.05.2024 | Accure Therapeutics awarded €1 million from Spanish government to evaluate ACT-03 for post-traumatic epilepsy | Read the full press release here:
https://accure.health/accure-therapeutics-awarded-e1-million-from-spanish-government-to-evaluate-act-03-for-post-traumatic-epilepsy/
|
| 29.04.2024 | deepull unveils 1 hour, direct-from-blood multiplex PCR test for 95% of sepsis-causing pathogens at ESCMID 2024 | You can read full text here:
https://www.globenewswire.com/news-release/2024/04/25/2869327/0/en/deepull-unveils-1-hour-direct-from-blood-multiplex-PCR-test-for-95-of-sepsis-causing-pathogens-at-ESCMID-2024.html |
| 11.04.2024 | Why Your Company Needs an AI Assistant: Patient Engagement from First Contact | In an era where digital transformation is reshaping healthcare, the industry is experiencing a significant shift towards more patient-centered services. AI-based virtual assistance is at the forefront of this transformation, providing seaml... |
| 22.03.2024 | Peptomyc Appoints Selwyn Ho to its Board of Directors | Barcelona, Spain, March 21st, 2024
Peptomyc S.L., a clinical stage company specialized in the development of protein therapeutics targeting the MYC oncoprotein for cancer treatment, today announced the appointment of Dr. Selwyn Ho, MB, BS, ... |
| 26.02.2024 | Peptomyc presents results of their Ph1 study of OMO-103 in advanced solid tumours. | OMO-103 is an inhibitor for MYC, one of the most wanted, long-considered, undruggable oncogenes. The trial has established the safety, tolerability and pharmacokinetic profile of OMO-103, advising on Ph2 design and identifying soluble facto... |
| 14.02.2024 | Nature Medicine: Peptomyc’s first MYC inhibitor, OMO-103, demonstrates safety and anti-tumor activity in a phase I clinical trial | Peptomyc is proud to announce that the results of the MYCure clinical trial have just been published in Nature Medicine
|
| 14.02.2024 | binx health Enters into National Distribution Agreement with Cardinal Health to Increase Access to the CLIA-waived, FDA-cleared binx io | You can read the whole article here:
https://mybinxhealth.com/news/binx-health-Enters-into-National-Distribution-Agreement-with-Cardinal-Health-to-Increase-Access
|
| 20.09.2023 | InBrain Neuroelectronics wins FDA breakthrough nod for intelligent network modulation system | InBrain Neuroelectronics announced today that it received FDA breakthrough device designation for its intelligent network modulation system.
You can read the whole new here:
|
| 19.09.2023 | Aliath Bioventures appoints Dr Philippe Monteyne and announces additional hires to further strengthen its Life Sciences Impact business |
Madrid, 19th of September 2023.- Aliath Bioventures, the healthcare impact investment platform of AltamarCAM Partners, appoints Philippe Monteyne, MD, PhD as a new Partner to reinforce the company’s healthcare investment team. As of 16th ... |
| 14.03.2023 | ACP Aliath Bioventures II FCR fund has been registered | Madrid, 14 March 2023.- AltamarCAM Partners, a global asset manager focused on investing in private markets, has registered its new fund ACP Aliath Bioventures II FCR (ABV II) in the CNMV. This is AltamarCAM‘s second healthcare venture fund... |
| 20.10.2022 | DeepUll raises €13M Series B financing to progress early sepsis recognition platform | Financing led by new investors Innvierte and an undisclosed strategic investor with participation from existing investors Kurma Partners, Alta Life sciences, UI Investissement and Axis
BARCELONA, Spain – October 20, 2022 – DeepUll, a medic... |
| 14.07.2022 | Study shows that selection of breast cancer patients for adjuvant bisphosphonate therapy based on Inbiomotion’s MAFTEST® reduces the risk of death in comparison with current clinical guidance | Barcelona, July 14 2022; Inbiomotion SL, a company developing a unique single-gene-based biomarker for the personalized adjuvant treatment of early-stage (stage I-III) breast cancer patients, announces the results of comparing the clinical ... |
| 02.03.2022 | Oculis Strengthens Leading Ophthalmology Pipeline by InLicensing Neuroprotective Drug Candidate for Glaucoma from Accure Therapeutics | Lausanne, Switzerland, and Barcelona, Spain, March 2, 2022 – Oculis S.A., (Oculis) a global ophthalmology company developing life-changing treatments to save sight and improve eye care with breakthrough innovations, and Accure Therapeutics,... |
| 18.01.2022 | Peptomyc logra 8,6 millones de sus socios y busca más inversores | https://www.expansion.com/catalunya/2022/01/17/61e5cb41468aeb02298b4662.html
Peptomyc_Expansion |
| 15.12.2021 | binx health Selected as a Top Digital Health Startup that is Transforming the Future of Healthcare — Named to the 2021 CB Insights Digital Health 150 List | https://www.businesswire.com/news/home/20211214005380/en/binx-health-Selected-as-a-Top-Digital-Health-Startup-that-is-Transforming-the-Future-of-Healthcare—-Named-to-the-2021-CB-Insights-Digital-Health-150-List |
| 10.12.2021 | binx health and Student Health Insurer, Wellfleet, Expand Agreement in College Health for In-Dorm and At-Home Access to Testing for Sexually Transmitted Infections (STIs) | http://mybinxhealth.com/news/binx-health-and-student-health-insurer-wellfleet-expand-agreement-in-college-health-for-in-dorm-and-at-home-access-to-testing-for-sexually-transmitted-infections-(stis) |
| 02.12.2021 | ONA Therapeutics Appoints Dr Michel Detheux as Independent Chair to Board of Directors | Seasoned biotech executive with a wealth of experience and a track-record of strategic alliances in the immuno-oncology space
Barcelona, Spain, 2 December 2021: ONA Therapeutics (“ONA”), which is focused on the discovery and development of... |
| 22.11.2021 | Vifor Pharma to acquire Sanifit to further strengthen late-stage pipeline in nephrology |
St. Gallen, Switzerland, and Palma, Spain, 19 November 2021 – Vifor Pharma and Sanifit Therapeutics, a clinical-stage cardio-renal biopharmaceutical company focused on treatments for progressive vascular calcification disorders, today ann... |
| 22.11.2021 | Vifor Pharma adquirirá Sanifit para reforzar su cartera de productos en fase avanzada en nefrología |
St. Gallen, Suiza, y Palma, España, 19 de noviembre de 2021 – Vifor Pharma y Sanifit Therapeutics, compañía biofarmacéutica cardio-renal en fase clínica centrada en tratamientos para trastornos de calcificación vascular progresiva, han ... |
| 21.10.2021 | ONA Therapeutics Strengthens Scientific Leadership Team | Barcelona, Spain, 21 October 2021: ONA Therapeutics (“ONA”), which is focused on the discovery and development of therapeutic biologics targeting lipid metabolism in order to treat advanced cancer, announces today the appointment of Dr Haij... |
| 04.10.2021 | DeepUll Appoints Richard Ivey to its Board of Directors | Diagnostics industry veteran with forty years’ experience to support DeepUll in its continued development of its early sepsis identification system
BARCELONA, Spain – October 4 2021 – DeepUll, a medical diagnostics company developing cultu... |
| 04.10.2021 | Mediktor raises €11m round for its AI- triage and pre-diagnosis medical assistant | Barcelona October 4th, 2021. Mediktor – the Spanish healthtech company which provides a sophisticated pre-diagnosis medical assistant – announced that it has raised a €11 million financing round to keep on improving their elaborate technolo... |
| 30.09.2021 | Inbiomotion’s MAF Test ® selects breast cancer patients benefitting from adjuvant clodronate, significantly improving their overall survival | • Level 1 evidence from the MAF Test ®analyses of the NSABP-B34 landmark clinical trial confirmed clinical utility of the MAF Test ® for selection of early-stage breast cancer patients that benefit from adjuvant clodronate treatment to prev... |
| 10.09.2021 | Graphene Flagship spin-off INBRAIN signs collaboration with Merck to develop next-generation bioelectronics | https://graphene-flagship.eu/graphene/news/graphene-flagship-spin-off-inbrain-signs-collaboration-with-merck-to-develop-next-generation-bioelectronics/ |
| 23.07.2021 | Spanish startups and scaleups to watch | https://sifted.eu/articles/spain-startups-top-ranking/ |
| 28.05.2021 | binx health Raises $104 Million in Series E Financing | https://mybinxhealth.com/news/binx-health-raises-104-million-in-series-e-financing/ |
| 18.05.2021 | binx health Submits Request for Emergency Use Authorization for First CRISPR-based Point-of-care Test for COVID-19 | https://mybinxhealth.com/news/binx-health-submits-request-for-emergency-use-authorization-for-first-crispr-based-point-of-care-test-for-covid-19/ |
| 06.05.2021 | PEPTOMYC SL Announces Treatment of First Patient with its Lead Compound OMO-103 in a Phase I/II Clinical Trial | Barcelona, Thursday 6th May 2021
Peptomyc, a Spanish clinical stage biotech company spin-off of the Vall d’Hebron Institute of Oncology (VHIO) and the Catalan Institute of Research and Advanced Studies (ICREA) in Barcelona, reported that o... |
| 30.03.2021 | FDA Allows for First Point-of-Care Chlamydia and Gonorrhea Test to be Used in More Near-Patient Care Settings | https://mybinxhealth.com/news/binx-health-receives-fda-clia-waiver-for-chlamydia-and-gonorrhea-test-expanding-critical-access-to-single-visit-diagnoses-2/ |
| 26.03.2021 | INBRAIN Neuroelectronics raises over €14M Series A led by Alta Life Sciences, Asabys Partners and CDTI to develop intelligent graphene-based neuroelectronic therapies for brain related disorders | Barcelona, March 26th , 2021
INBRAIN Neuroelectronics is a spin-off company from Graphene Flaship partners’ the Catalan Institute of Nanoscience and Nanotechnology (ICN2) and ICREA, established in 2019 in the intersection between Medtech, ... |
| 18.03.2021 | binx health™ Collaborates with Amazon Business for Delivery of COVID-19 Sample Collection Kits to U.S. Businesses, Schools and Governments | https://mybinxhealth.com/news/binx-health-collaborates-with-amazon-business-for-delivery-of-covid-19-sample-collection-kits-to-u-s-businesses-schools-and-governments/ |
| 18.03.2021 | Green light by the AEMPS to start clinical trials with OMO-103 | http://www.peptomyc.com/green-light-by-the-aemps-to-start-clinical-trials-with-omo-103/ |
| 11.03.2021 | Veteran Healthcare Leader David P. King Joins binx health Board of Directors | -Former LabCorp Chairman and CEO joins binx board during period of rapid growth-
BOSTON, MA, [DATE]– binx health today announced the addition of David P. King to its Board of Directors. Mr. King served for nearly 13 years as Chairman and C... |
| 05.03.2021 | ONA Therapeutics appoints Mark Throsby to its Board of Directors | Barcelona, Spain, March 5th, 2021: Ona Therapeutics, a company focused on the discovery and development of therapeutic biologics to treat metastatic cancer, announces today that it has appointed Dr. Mark Throsby as independent board member ... |
| 02.03.2021 | Accure Therapeutics enrols first patient in phase II clinical trial on acute optic neuritis with lead candidate ACT-01 | https://accure.health/accure-therapeutics-enrols-first-patient-in-phase-ii-clinical-trial-on-acute-optic-neuritis-with-lead-candidate-act-01/ |
| 25.02.2021 | Alta Life Sciences participa en el grupo de trabajo de AseBio para impulsar el sector biotech | https://www.asebio.com/actualidad/noticias/asebio-une-las-principales-gestoras-especializadas-de-capital-riesgo-para |
| 21.02.2021 | binx health Enters into Distribution Agreement for National Launch of the FDA-cleared binx io | https://mybinxhealth.com/news/binx-health-enters-into-distribution-agreement-for-national-launch-of-the-fda-cleared-binx-io/ |
| 12.02.2021 | Accure Therapeutics publishes pivotal preclinical efficacy study in epilepsy | https://accure.health/accure-therapeutics-publishes-pivotal-preclinical-efficacy-study-in-epilepsy/ |
| 11.02.2021 | Sanifit Granted Orphan Drug Designation by the FDA for SNF472 for the Treatment of Peripheral Arterial Disease in Patients with End-stage Kidney Disease | https://www.sanifit.com/sanifit-granted-orphan-drug-designation-by-the-fda-for-snf472-for-the-treatment-of-peripheral-arterial-disease-in-patients-with-end-stage-kidney-disease/ |
| 10.02.2021 | Accure Therapeutics – Webinars on Neuroprotection for Brain Diseases Program | https://accure.health/webinars-on-neuroprotection-for-brain-diseases-program/ |
| 09.02.2021 | Alta Life Sciences engorda en el año del Covid-19: el fondo de Altamar invierte veinte millones | https://www.plantadoce.com/empresa/alta-life-sciences-engorda-en-el-ano-del-covid-19-el-fondo-de-altamar-invierte-veinte-millones.html |
| 26.01.2021 | Accure Therapeutics appoints Dr. Rossella Medori as chief medical officer | https://accure.health/accure-therapeutics-appoints-dr-rossella-medori-as-chief-medical-officer/ |
| 21.01.2021 | Alta Life Sciences leads an oversubscribed investment round into Inbiomotion to launch its diagnostic product in breast cancer | • The financing round is led by Alta Life Sciences Spain I FCR, a vehicle managed by Altamar Private Equity SGIIC. Existing investors including Institut Català de Finances (ICF) have also participated in the financing.
• Inbiomotion is in ... |
| 12.01.2021 | Accure Therapeutics strengthens scientific advisory board by appointing top-class scientists | Five neurology experts join CNS specialist’s scientific advisory board to support clinical trial development of disease modifying drug candidates
Barcelona, Spain, January 11, 2021 – Accure Therapeutics, a private translational R&D eng... |
| 11.01.2021 | Peptomyc Board of Directors appoints Giacomo Di Nepi as Chairman of the Board | - |
| 11.01.2021 | Sanifit to Participate in the 2021 ICR Conference | - |
| 11.01.2021 | Binx health receives EUA authorizing At-Home COVID-19 sample collection by universities and employers | - |
| 11.01.2021 | Peptomyc steps forward as a Clinical Stage Biotech company | - |
| 11.01.2021 | SANIFIT – Subgroup Analyses from Sanifit’s CaLIPSO Phase 2b Clinical Study Published in Kidney International Reports | - |
| 16.12.2020 | Peptomyc announces a new equity financing round of 11.4M€ | This investment will help Peptomyc lead its drug candidate OMO103 into clinical phase I/II as a treatment for solid tumors
Barcelona, Spain, December 15, 2020 – Peptomyc S.L., a biotech company specialized in the development of protein and... |
| 07.07.2020 | DeepUll closes Series A Financing led by Alta Life Sciences and Kurma Partners, to improve early diagnosis of sepsis |
Barcelona, 7 July 2020.- DeepUll announced today the closing of a 3.5 million Euro round Series A financing led by Alta Life Sciences and Kurma Partners and with participation from Axis Participaciones Empresariales and Sofimac Innovati... |
| 16.06.2020 | Alta Life Sciences invests in Ona Therapeutic’s €30M Series A | Barcelona, Spain, June 16th 2020: Ona Therapeutics, which is focused on the discovery and development of therapeutic biologics to treat metastatic cancer, announces today the closing of a €30 million Series A financing, with participation f... |
| 11.06.2020 | SABADELL ASABYS Y ALTA LIFE SCIENCES APUESTAN POR EL GRAFENO EN EL ÁMBITO DE LAS TERAPIAS ELECTRONICAS NEURONALES Y COLIDERAN LA INVERSIÓN EN INBRAIN NEUROELECTRONICS | Barcelona, 17 de junio de 2020
INBRAIN desarrolla dispositivos de grafeno inteligentes para la modulación electrónica neuronal contra trastornos cerebrales como el Parkinson y la Epilepsia entre otros
INBRAIN, spin-off del Instituto Catal... |
| 01.06.2020 | Sanifit Enhances Leadership Team with New Executive Appointments | Newly appointed VP of Business Development and SVP of Clinical Development each bring to Sanifit over 20 years of industry experience
Palma, Spain and San Diego, USA, 01 June 2020 – Sanifit, a clinical-stage biopharmaceutical company focus... |
| 27.05.2020 | Accure Therapeutics launches with €7.6M Series A round | Alta Life Sciences and the Centre for Technological and Industrial Development (CDTI) invest in new company that will develop portfolio of new medicines to address CNS diseases
Barcelona, Spain, May 26, 2020 – Accure Therapeutics, a new ph... |
| 31.10.2019 | Sanifit announces that the Phase 2b CaLIPSO trial of SNF472 met its primary endpoint in slowing the progression of cardiovascular calcification in patients on hemodialysis. | Top line data to be presented at 2019 Scientific Sessions of American Heart Association
Webcast to be held on Monday 18 November at 11.00 ET
Palma, Spain and San Diego, USA, 30 October 2019 – Sanifit, a clinical-stage biopharmaceutical co... |
| 26.09.2019 | Sanifit named as one of 2019’s “Fierce 15” biotechnology companies by FierceBiotech | Sanifit, a clinical-stage biopharmaceutical company focused on treatments for progressive vascular calcification disorders that is part of Alta Life Sciences portfolio, has been named by FierceBiotech as one of 2019’s Fierce 15 biotechnolog... |
| 28.06.2019 | Alta Life Sciences participates in Sanifit’s 55,2M€ Series D round led by Caixa Capital Risc | Palma, Spain and San Diego, USA, 26 June 2019 – Sanifit, a clinical-stage biopharmaceutical company focused on treatments for progressive vascular calcification disorders, today announced the completion of a €72.2 million (USD 80.9 million)... |
| 13.09.2018 | Mediktor closes a funding round of 3 million euros with the aim of entering the US market | - |
| 17.05.2018 | Alta Life Sciences is leading a 4M € round to finance the clinical development of the Bionures’s neuroprotector BN201 | Alta Life Sciences is leading a Series A round of 4 million euros to finance the clinical development of Bionure’s lead compound BN201, that has demonstrated its potential to promote neuroprotection and remyelination in the preclinical phas... |
| 06.09.2017 | Peptomyc S.L. secures 4.2 million euros in Series A led by Alta Life Sciences | Peptomyc S.L., a Barcelona-based biotech company developing new peptide therapeutics for the treatment of cancer patients, announces the closure of a Series A financing of 4.2 million euros. The investment round was led by Alta Life Science... |
